SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
ROCKVILLE, Md., Oct. 24, 2017 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the third quarter of 2017 after 5:00 PM ET on Monday, November 6, 2017.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the third quarter 2017 business results on Tuesday, November 7, 2017 at 9:00 AM ET. Following the management presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | |
| International dial-in: | (970) 315-0267 | |
| Conference ID: | 2899017 | |
| Conference Call Name: | Supernus Pharmaceuticals 3Q 2017 Earnings Conference Call |
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
